Boston Scientific (NYSE:BSX) Raised to "Buy" at Deutsche Bank Aktiengesellschaft

Boston Scientific (NYSE:BSX - Get Free Report) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Friday, MarketBeat reports. The brokerage currently has a $108.00 price objective on the medical equipment provider's stock. Deutsche Bank Aktiengesellschaft's price target indicates a potential upside of 13.52% from the stock's current price.

Other equities analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. increased their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an "overweight" rating in a research report on Monday, December 16th. TD Cowen raised their price objective on Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a research note on Thursday, December 12th. Morgan Stanley boosted their price target on shares of Boston Scientific from $92.00 to $100.00 and gave the company an "overweight" rating in a research note on Thursday, October 24th. BTIG Research raised their price objective on shares of Boston Scientific from $84.00 to $93.00 and gave the company a "buy" rating in a research note on Monday, October 14th. Finally, Citigroup upped their target price on shares of Boston Scientific from $98.00 to $107.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $97.26.

Boston Scientific Trading Down 0.8 %

NYSE BSX traded down $0.81 during trading hours on Friday, hitting $95.14. 5,901,236 shares of the company's stock were exchanged, compared to its average volume of 5,541,849. Boston Scientific has a 1-year low of $59.39 and a 1-year high of $97.13. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The stock has a 50-day simple moving average of $89.73 and a 200 day simple moving average of $83.67. The firm has a market cap of $140.22 billion, a price-to-earnings ratio of 78.63, a PEG ratio of 2.67 and a beta of 0.80.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.04. The company had revenue of $4.21 billion during the quarter, compared to analyst estimates of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. Boston Scientific's revenue for the quarter was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.50 EPS. On average, equities analysts forecast that Boston Scientific will post 2.46 EPS for the current fiscal year.

Insiders Place Their Bets

In other Boston Scientific news, EVP John Bradley Sorenson sold 4,119 shares of the business's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total transaction of $370,792.38. Following the sale, the executive vice president now owns 35,319 shares of the company's stock, valued at $3,179,416.38. The trade was a 10.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Wendy Carruthers sold 6,983 shares of the firm's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $90.78, for a total value of $633,916.74. Following the completion of the transaction, the executive vice president now directly owns 29,308 shares of the company's stock, valued at $2,660,580.24. The trade was a 19.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,989 shares of company stock valued at $2,702,261 over the last ninety days. 0.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Values First Advisors Inc. purchased a new stake in shares of Boston Scientific in the 3rd quarter valued at about $28,000. Dunhill Financial LLC increased its holdings in shares of Boston Scientific by 86.4% in the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock worth $28,000 after buying an additional 152 shares during the last quarter. Global Wealth Strategies & Associates raised its position in shares of Boston Scientific by 423.7% during the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock valued at $28,000 after buying an additional 250 shares in the last quarter. Andra AP fonden bought a new stake in shares of Boston Scientific during the 2nd quarter worth $29,000. Finally, E Fund Management Hong Kong Co. Ltd. purchased a new position in Boston Scientific in the third quarter worth $30,000. Institutional investors own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.